Key result
Drug-eluting stents significantly decreased the re-stenosis rate compared with bare metal stents in both diabetic (9.6% vs 21.3%) and non-diabetic (9.5% vs 17.1%) patients.
Why the study?
Does PCI using a drug-eluting stent reduce re-stenosis compared to bare metal stent in patients with coronary artery disease with or without diabetes mellitus?
Cohort (n=6,739)
Does PCI using a drug-eluting stent reduce re-stenosis compared to bare metal stent in patients with coronary artery disease with or without diabetes mellitus?
Absolute Event Rate: 9.6% vs 21.3%
Drug-eluting stents significantly reduce re-stenosis rates compared to bare metal stents in both diabetic and non-diabetic patients with coronary artery disease, though event-free survival in left main disease showed no significant difference.
Supports lower re-stenosis with drug-eluting stents regardless of diabetes; leaves open whether findings warrant practice change pending randomized data.
Percutaneous coronary intervention (PCI) using a drug-eluting stent (DES) leads to less re-stenosis than PCI using a bare metal stent (BMS), however there is still controversy whether use of a DES for severe coronary disease leads to an acceptable outcome in patients with diabetes mellitus (DM). In this study 8159 lesions were treated in 6739 patients (mean age 68.9 years) with coronary artery disease. Use of a DES significantly decreased the re-stenosis rate compared with BMS in both DM (9.6% versus 21.3%) and non-DM (9.5% versus 17.1%) patients. The re-stenosis rate was significantly higher in DM than in non-DM patients in the BMS group but not in the DES group. There was no statistically significant difference in event-free survival after stenting of patients with left main coronary artery (LMCA) disease between the BMS and DES groups. It was concluded that, compared with BMS, DES reduced re-stenosis in patients with DM, however, we advise careful treatment after using DES for severe coronary disease, including LMCA lesions, in patients with DM.
No takes yet. Share an insight, caveat, or question.
Uchiyama et al. (2011) conducted a cohort in coronary artery disease (n=6,739). Drug-eluting stent (DES) vs. Bare metal stent (BMS) was evaluated on re-stenosis rate in patients with diabetes mellitus. Drug-eluting stents significantly decreased the re-stenosis rate compared with bare metal stents in both diabetic (9.6% vs 21.3%) and non-diabetic (9.5% vs 17.1%) patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: